Gupta, Shilpa
Moon, Helen H.-S.
Sridhar, Srikala S.
Funding for this research was provided by:
Merck
Article History
Accepted: 17 May 2024
First Online: 4 July 2024
Declarations
:
: This podcast was funded by Merck (CrossRef Funder ID: 10.13039/100009945).
: The authors received no honoraria related to the development of this publication. Shilpa Gupta has served in consulting or advisory roles for Bayer, Bristol Myers Squibb, Gilead Sciences, Guardant Health, Merck, MSD, Pfizer, and Seagen; has reported speakers services for Astellas Pharma, Bristol Myers Squibb, Gilead Sciences, Janssen Oncology, and Seagen; and has stock and other ownership interests in BioNTech and Nektar Therapeutics. Helen H.-S. Moon has received honoraria from Merck and Pfizer and has received institutional research funding from Amgen, Apollomics, Arcus Biosciences, AVEO, Bristol Myers Squibb, Genentech, HUYA Bioscience International, Nektar, Prometheus, Revimmune, and Seagen. Srikala S. Sridhar has served in consulting or advisory roles for their institution for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, MSD, Pfizer, Roche/Genentech, and Seagen and has received institutional research funding from Bayer, Janssen, and Pfizer.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Shilpa Gupta, Helen H.S. Moon, and Srikala S. Sridhar contributed equally to all aspects of the development of this podcast, including concept and design, drafting of the outline, and interpretation of the data discussed.